Sequana Medical NV
XBRU:SEQUA

Watchlist Manager
Sequana Medical NV Logo
Sequana Medical NV
XBRU:SEQUA
Watchlist
Price: 2.76 EUR 33.33% Market Closed
Market Cap: 122.6m EUR
Have any thoughts about
Sequana Medical NV?
Write Note

Sequana Medical NV
Common Shares Outstanding

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Sequana Medical NV
Common Shares Outstanding Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Common Shares Outstanding CAGR 3Y CAGR 5Y CAGR 10Y
Sequana Medical NV
XBRU:SEQUA
Common Shares Outstanding
€35.9m
CAGR 3-Years
25%
CAGR 5-Years
23%
CAGR 10-Years
N/A
Nyxoah SA
XBRU:NYXH
Common Shares Outstanding
€28.7m
CAGR 3-Years
9%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Biocartis Group NV
XBRU:BCART
Common Shares Outstanding
€93m
CAGR 3-Years
13%
CAGR 5-Years
13%
CAGR 10-Years
N/A
Ion Beam Applications SA
XBRU:IBAB
Common Shares Outstanding
€29.2m
CAGR 3-Years
-1%
CAGR 5-Years
0%
CAGR 10-Years
N/A
No Stocks Found

Sequana Medical NV
Glance View

Market Cap
122.6m EUR
Industry
Health Care

Sequana Medical NV is a commercial stage medical device company, which engages in the design, development, manufacture, and commercialization of medical device. The company is headquartered in Ghent, Oost-Vlaanderen and currently employs 60 full-time employees. The company went IPO on 2019-02-11. The firm focuses mainly on the development of treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders. Sequana Medical NV provides alfapump, which is an implantable, programmable, wireless-charged and battery-powered system that is CE-marking for the management of refractory ascites due to liver cirrhosis and malignant ascites. Over 650 alfapump systems have been implanted. Apart from the Alfapump, the Company also aims to develop a direct sodium removal (DSR) therapy, which is a propriety approach to the treatment of volume overload in heart failure.

SEQUA Intrinsic Value
1.56 EUR
Overvaluation 43%
Intrinsic Value
Price

See Also

What is Sequana Medical NV's Common Shares Outstanding?
Common Shares Outstanding
35.9m EUR

Based on the financial report for Jun 30, 2024, Sequana Medical NV's Common Shares Outstanding amounts to 35.9m EUR.

What is Sequana Medical NV's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 5Y
23%

Over the last year, the Common Shares Outstanding growth was 27%. The average annual Common Shares Outstanding growth rates for Sequana Medical NV have been 25% over the past three years , 23% over the past five years .

Back to Top